Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

Update information

Minor changes since publication

June 2021: Recommendation 1.6 added on equality when using the disease activity score.

September 2019: Contact details for Bristol-Myers Squibb, Roche, Merck, Sharp & Dohme and UCB Pharma have been put on the overview page.

ISBN: 978‑1‑4731‑1630‑6